IDH2型
髓系白血病
耐火材料(行星科学)
药效学
医学
髓样
胃肠病学
药代动力学
不利影响
肿瘤科
内科学
药理学
突变体
生物
IDH1
基因
天体生物学
生物化学
作者
Eytan M. Stein,Courtney D. DiNardo,Daniel A. Pollyea,Amir T. Fathi,Gail J. Roboz,Jessica K. Altman,Richard M. Stone,Daniel J. DeAngelo,Ross L. Levine,Ian W. Flinn,Hagop M. Kantarjian,Robert H. Collins,Manish R. Patel,Arthur E. Frankel,Anthony S. Stein,Mikkael A. Sekeres,Ronan T. Swords,Bruno C. Medeiros,Christophe Willekens,Paresh Vyas
出处
期刊:Blood
[Elsevier BV]
日期:2017-06-07
卷期号:130 (6): 722-731
被引量:1313
标识
DOI:10.1182/blood-2017-04-779405
摘要
Key Points Enasidenib, a selective inhibitor of mutant IDH2 enzymes, was safe and well tolerated in patients with IDH2-mutated myeloid malignancies. Enasidenib induced hematologic responses in patients with relapsed/refractory AML in this dose-escalation and expansion study.
科研通智能强力驱动
Strongly Powered by AbleSci AI